PRIMARY STUDY
Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin Renal Evaluation Trial (FRET)
Key Findings: In patients with chronic kidney disease (CKD) the lipid-lowering drug fluvastatin was renoprotective as evidenced by reduced levels of urinary albumin excretion (UAE) and liver-type fatty acid binding protein (L-FABP).
Type of Study: Clinical Trial
Study Sample Size: 43
Study Result: Positive
Study Location(s): Japan
Year of Pub: 2011
Cannabinoids Studied: Fatty Acid-Binding Protein (FABP)
Phytocannabinoid Source: Not Applicable
